


In re: Davies et al.
Serial No.: to be assigned
Filed: concurrently herewith
Page 4 of 7

Remarks

The above amendments are made to more clearly define the invention under United States practice. Please enter this amendment prior to calculation of the filing fee.

Respectfully submitted,



F. Michael Sajovec
Registration No. 31,793

USPTO Customer No.:



20792


PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING

Express Mail Label No. EL 733095067 US

Date of Deposit: September 7, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: BOX PATENT APPLICATION, Commissioner for Patents, Washington, DC 20231.



Monica L. Croom
September 7, 2001

In re: Davies et al.
Serial No.: to be assigned
Filed: concurrently herewith
Page 5 of 7

Version With Markings to Show Changes

In the specification:

Please amend the specification as follows:

At page one, below the title "NEURODEGENERATIVE DISORDER RELATED GENE," please insert -- This application claims priority from PCT Application No. PCT/GB00/00860, filed March 9, 2000, the disclosure of which is incorporated by reference herein in its entirety.--

In the Claims:

Please amend Claims 4, 8, 12, 16-17, 20, 22, 26-27, 30-31, 41, and 43-44.

4. (Amended) Use of a polynucleotide fragment according to [any preceding claim] claim 1 wherein the degenerative disorder is a degenerative disorder of the central nervous system.

8. (Amended) Use of a polynucleotide fragment according to [either of claims 6 or 7] claim 6 wherein the neurodegenerative disorder is selected from the group comprising Parkinson's Disease, Huntington's Disease/Chorea, Dementia with Lewy bodies, Multiple-system atrophy, Progressive supranuclear palsy, cortical-basal ganglionic (corticobasal) degeneration, vascular Parkinsonism and ballism.

12. (Amended) Use of a polypeptide according to [any of claims 9 to 11] claim 9 wherein a degenerative disorder is a degenerative disorder of the central nervous system.

16. (Amended) Use of a polypeptide according to [either of claims 14 or 15] claim 15 wherein the neurodegenerative disorder is selected from the group comprising Parkinson's Disease, Huntington's Disease/Chorea, Dementia with Lewy bodies, Multiple-system atrophy, Progressive supranuclear palsy, cortical-basal ganglionic (corticobasal) degeneration,

vascular Parkinsonism and ballism.

17. (Amended) Use of a polypeptide according to **[any of claims 9 to 16]** claim 9 wherein the polypeptide is synthetic.

20. (Amended) A method according to **[either of claims 18 or 19]** claim 18 wherein the animal is a mammal.

22. (Amended) A method according to **[either of claims 18 and 19]** claim 18 wherein the neurodegenerative disorder is a degenerative disorder of the central nervous system.

26. (Amended) A method according to **[either of claims 24 or 25]** claim 24 wherein the neurodegenerative disorder is selected from the group comprising Parkinson's Disease, Huntington's Disease/Chorea, Dementia with Lewy bodies, Multiple-system atrophy, Progressive supranuclear palsy, cortical-basal ganglionic (corticobasal) degeneration, vascular Parkinsonism and ballism.

27. (Amended) A method according to **[either of claims 18 or 19]** claim 18 wherein the mutation results in a truncated product from the PKC γ gene being produced.

30. (Amended) A method according to **[either of claims 18 or 19]** claim 18 wherein detection of the presence of the mutation in the PKC γ gene is achieved by detecting altered levels of the mRNA transcripts or mRNA precursor.

31. (Amended) A method according to **[either of claims 18 or 19]** claim 18 wherein the mutation in the PKC γ gene is detected using antibodies raised to the truncated PKC type I polypeptide.

In re: Davies et al.
Serial No.: to be assigned
Filed: concurrently herewith
Page 7 of 7

41. (Amended) An antibody according to [any of claims 38 to 40] claim 38 wherein the antibody is a monoclonal antibody.

43. (Amended) Use of an antibody according to [claims 38-42] claim 38 for the manufacture of a medicament for preventing, delaying, treating or inhibiting degeneration of the nervous system.

44. (Amended) Use of an antibody according to [claims 38-47] claim 38 in a diagnostic assay for testing an human thought to have or be predisposed to having a neural degenerative disorder.

Abstract:

At page 58, the page following the claims, please insert --The present invention relates to the use of a polynucleotide fragment comprising PKC γ gene including type 1 subtype of protein kinase C in the manufacture of a medicament for treating a neurodegenerative disorder. The invention further relates to use of a polypeptide which comprises protein kinase C type 1 in the manufacture of a medicament for treating a neurodegenerative disorder. Further disclosed is a method of testing an animal, such as human, thought to have or be predisposed to having a neurodegenerative disorder which comprises detecting the presence of a mutation in PKC γ gene and/or its associated promoter.--